EUVIMEDEUVIMED entdecken
Crossref

Solid Lipid Nanoparticles Encapsulated With Paromomycin: An Effective Oral Formulation Against Leishmania major in Mouse Model

Maryam Heidari-Kharaji iD, Priscilla Rodrigues, Christina Petersen

Parasite Immunology · 2025

DOI: 10.1111/pim.70002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Parasite Immunology, 2025. Verfasst von Maryam Heidari-Kharaji und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, Missouri, USA. Hauptthemen laut MEDLINE: Paromomycin, Nanoparticles, Antiprotozoal Agents, Leishmania major. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leishmaniasis is a disease caused by protozoan parasites of the genus Leishmania . The treatment of intracellular infections such as leishmaniasis is often challenging due to limited drug access to infected cells and the development of drug resistance. Therefore, the development of new antileishmanial compounds is essential. Paromomycin sulphate (PM) has shown promise as an antileishmanial drug, and one way to enhance its effectiveness is through appropriate delivery systems. Solid lipid nanoparticles (SLN) are being explored as a potential delivery system for PM, as they offer advantages over other colloidal carriers. In a recent study, PM was loaded into solid lipid nanoparticles (PM‐SLN) and its oral effectiveness was evaluated in treating Leishmania (L.) major ‐infected mice. The study measured footpad swelling, quantified parasite load through real‐time PCR and assessed levels of cytokines such as interleukin‐4 (IL‐4) and gamma interferon (IFN‐c), nitric oxide (NO) and Arginase (ARG). Overall, the study demonstrated that oral administration of the PM‐SLN formulation is safe and effective in treating leishmaniasis. The SLN in the PM‐SLN compound improved the killing of parasites by PM and stimulated a Th1 immune response, indicating its potential as a treatment for leishmaniasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ParomomycinNanoparticlesAntiprotozoal AgentsLeishmania majorLeishmaniasis, CutaneousDrug CarriersAnimalsAdministration, OralDisease Models, AnimalMiceMice, Inbred BALB CParasite LoadFemaleLipidsNitric OxideCytokines

Stichwörter der Autor:innen

cutaneous leishmaniasiscytokinedrug delivery systemparomomycin sulphatesolid lipid nanoparticletherapy

Substanzen

ParomomycinAntiprotozoal AgentsLipidsNitric OxideDrug CarriersCytokines

Autor:innen und Institutionen

  • Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, Missouri, USA.
  • Institute National de la Recherche Scientifique (INRS)-Centre Armand-Frappier SantéBiotechnologie (CAFSB), Quebec, Canada.
  • Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada.
  • Faculty of Science, McGill University, Montreal, Quebec, Canada.

ORCID-Profile: Maryam Heidari-Kharaji

Zitieren

APA

Heidari-Kharaji, M., Rodrigues, P., & Petersen, C. (2025). Solid Lipid Nanoparticles Encapsulated With Paromomycin: An Effective Oral Formulation Against Leishmania major in Mouse Model. Parasite Immunology. https://doi.org/10.1111/pim.70002

Vancouver

Heidari-Kharaji M, Rodrigues P, Petersen C. Solid Lipid Nanoparticles Encapsulated With Paromomycin: An Effective Oral Formulation Against Leishmania major in Mouse Model. Parasite Immunology. 2025. doi:10.1111/pim.70002

BibTeX
@article{HeidariKharaji2025,
  author = {Heidari-Kharaji, Maryam and Rodrigues, Priscilla and Petersen, Christina},
  title = {Solid Lipid Nanoparticles Encapsulated With Paromomycin: An Effective Oral Formulation Against Leishmania major in Mouse Model},
  journal = {Parasite Immunology},
  year = {2025},
  doi = {10.1111/pim.70002}
}
Kostenlos starten →